Proximal renal tubular acidosis secondary to FK506 in pediatric liver transplant patients.
We hereby report our experience with an index case of a pediatric liver transplant patient in whom FK506 administration was associated with the development of proximal renal tubular acidosis (RTA), as well the prevalence of acidosis and renal dysfunction in all pediatric liver transplant patients in our institution followed long term during a 6-year period. Data were grouped according to immunosuppressant regime: cyclosporine (CsA) only, FK506 only, or CsA with conversion to FK506. A 23-month-old female treated with FK506 after orthotopic liver transplantation (OLT) performed 15 months earlier presented with a 1-wk history of fever, watery diarrhea and metabolic acidosis. Although the acidosis did not improve following correction of her hydration status, administration of oral bicarbonate was effective. Discontinuation of this therapy resulted in acidosis. Since other indirect measurements of renal tubular function were normal, the patient was judged to have an isolated proximal RTA. In our group of pediatric liver transplant patients converted from CsA to FK506, FK506 administration was associated with a decline in serum bicarbonate (19 +/- 1 vs. 16 +/- 1 mEq/l, p < 0.02); neither blood urea nitrogen nor serum creatinine differed between the two groups. The number of rejection episodes/patient/month was comparable, allowing clinically relevant comparison of relative drug nephrotoxicities. We conclude that proximal RTA may be a relatively common treatable complication of FK506 administration in children.
O'Gorman
M A
MA
Johns Hopkins University School of Medicine, Department of Pediatrics, Baltimore, Maryland, USA.
Fivush
B
B
Wise
B
B
Colombani
P
P
Burdick
J
J
Schwarz
K B
KB
D000141:Acidosis, Renal Tubular / Q000139:chemically induced* / Q000188:drug therapy; D000284:Administration, Oral; D001639:Bicarbonates / Q000008:administration & dosage / Q000097:blood / Q000627:therapeutic use; D001806:Blood Urea Nitrogen; D002648:Child; D003404:Creatinine / Q000097:blood; D016572:Cyclosporine / Q000009:adverse effects; D003968:Diarrhea, Infantile / Q000139:chemically induced; D005260:Female; D005440:Fluid Therapy; D005500:Follow-Up Studies; D006084:Graft Rejection / Q000517:prevention & control; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects*; D007223:Infant; D007674:Kidney Diseases / Q000139:chemically induced; D007687:Kidney Tubules, Proximal / Q000187:drug effects*; D016031:Liver Transplantation; D008137:Longitudinal Studies; D015995:Prevalence; D016559:Tacrolimus / Q000009:adverse effects*
D001639:Bicarbonates; D007166:Immunosuppressive Agents; D016572:Cyclosporine; D003404:Creatinine; D016559:Tacrolimus